[시장보고서]아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 보고서 : 범위, 부문, 역학, 경쟁 분석(2021-2031년)

아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 보고서 : 범위, 부문, 역학, 경쟁 분석(2021-2031년)

Asia Pacific Pharmacovigilance and Drug Safety Software Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

상품코드 : 1819688 해당 상품은 즉시 배송 가능합니다

리서치사 : The Insight Partners

발행일 : 2025년 07월

페이지 정보 : 영문 227 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,450

￦ 4,981,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,424,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,450

￦ 7,868,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장은 2023년에 약 4,440만 달러로 평가되었으며, 2031년에는 6,866만 달러, 2023년부터 2031년까지 CAGR 5.6%로 성장할 것으로 예상됩니다.

이 시장 확대의 주요 요인은 인공지능(AI), 머신러닝(ML), 자연언어 처리(NLP)와 같은 첨단 기술의 통합입니다. 이러한 기술은 약물감시와 관련된 종래에는 자원 집약적이었던 프로세스에 혁명을 가져오고, 보다 많은 정보에 근거한 효율적인 업무로 인도하고 있습니다. 최신의 약물감시 소프트웨어 플랫폼은 안전 신호 식별을 강화하는 고급 분석 및 AI 기능을 갖추고 있습니다. 대규모 데이터 세트를 분석함으로써 이러한 도구는 전통적인 방법으로 놓칠 수 있는 상관관계와 패턴을 발견할 수 있습니다. 또한 AI를 활용한 예측 분석을 통해 잠재적인 안전 문제를 예측할 수 있기 때문에 기업은 사전 조치를 취할 수 있습니다.

머신러닝 모델은 의약품 사용과 관련된 부작용을 예측하는 데 특히 유용합니다. 예를 들어, 약물감시 이니셔티브는 ML을 활용하여 광범위한 데이터 세트를 분석하고 부작용의 위험을 시사하는 패턴을 확인합니다. 이러한 알고리즘은 소셜 미디어 컨텐츠 및 환자 기록과 같은 비정형 데이터 처리에 탁월하며 안전성 문제를 효과적으로 예측할 수 있습니다.

이 시장에서는 제약 회사의 의약품 개발을 촉진하기 위해 여러 주요 기업이 AI 기반 자동 모니터링 도구를 개발하고 있습니다. 주목할 만한 점은 2021년 5월에 Clarivate가 AI가 주도하는 약물감시 문헌 모니터링 소프트웨어 플랫폼인 DialogML을 발표한 것입니다. 이 도구는 약물감시 문헌의 모니터링을 자동화하고 집계 보고 및 안전 신호 검토와 같은 프로세스를 간소화합니다. 2024년 1월, PubHive Ltd.는 인공지능을 활용한 약물감시 워크플로우를 통합한 혁신적인 제품 특성 요약(SmPC) 중앙 집중식 관리 플랫폼을 발표했습니다. 이 플랫폼은 생명과학, 제약회사, 임상연구기관(CRO)을 위해 설계되었으며 약물감시 팀의 컴플라이언스와 업무 효율성을 높입니다.

임상시험 데이터, 의학문헌 검토, 부작용(AE)을 확인하기 위한 환자등록 등을 다루는 실시간 의약품 안전 모니터링은 AI 시스템의 이용이 점점 대중화되고 있습니다. 이 프로액티브 접근법은 부작용(ADR) 검출의 정확성과 속도를 향상시킵니다. 또한 NLP 기술을 통해 AI 시스템은 방대한 텍스트 데이터 세트에서 약물 이름 및 증상과 같은 적절한 정보를 추출하여 신속하고 정확한 부작용 보고를 촉진할 수 있습니다. 이 기능은 새로운 또는 이전에 알려지지 않은 의약품의 안전성 문제를 식별하는 것을 가속화하고 약물감시의 노력을 크게 향상시킵니다.

아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장은 인도, 중국, 일본, 한국, 호주, 기타 아시아태평양 등 다양한 국가로 구분됩니다. 이 지역에서는 의료 및 의약품 분야의 디지털화가 급속히 진행되고 있습니다. 예를 들어, 인도 정부는 Ayuschman Baratt Digital Mission과 CoWIN 앱과 같은 건강 관리에 대한 접근성을 향상시키기 위해 여러 프로그램을 시작했습니다. 마찬가지로 호주도 의료 및 제약 분야의 현대화를 위해 노력하고 있으며, 2022년 3월에 발표된 7만 4,910달러(10만 7,200달러)의 투자는 주목할 만합니다.

약물감시 및 의약품 안전성 소프트웨어의 AI 통합은 의약품 안전 데이터를 모니터링, 수집, 분석 및 관리하기 위해 이러한 시스템을 활용하는 제약 회사들 사이에서 널리 사용되고 있습니다. 지역 전체에서 약물감시 수요가 높아짐에 따라 첨단 소프트웨어 솔루션의 채택으로의 변화가 현저해지고 있습니다. 이러한 도구는 시판 전, 시판 후 조사 및 임상시험 중 등 의약품 개발의 다양한 단계를 통해 채택되고 있습니다. 그 결과, 제약업계의 디지털화에 대한 노력이 증가하고 약물감시 소프트웨어의 채택이 증가하고 있는 것이 아시아태평양에서 시장 성장의 원동력이 될 것으로 예측됩니다.

시장은 또한 제공 제품, 배포 방법, 기업 규모, 소프트웨어 형태, 기능, 최종 사용자에 따라 분류됩니다. 제공 제품의 경우 시장은 소프트웨어 및 서비스로 나뉘며 2023년에는 소프트웨어 부문이 더 큰 점유율을 차지하고 있습니다. 배포와 관련하여 클라우드 기반 솔루션이 선호됨을 반영하여 클라우드 부문도 큰 시장 점유율을 얻고 있습니다.

기업 규모의 경우 대기업은 시장을 독점하고 있으며 소프트웨어 형태는 표준 솔루션과 맞춤형 솔루션으로 분류되며 표준 소프트웨어는 시장 점유율을 이끌고 있습니다. 기능별로 볼 때 시장에는 신호 위험 관리, 부작용 추적, 사례 관리, 임상 안전 관리 등의 부문이 있으며, 신호 위험 관리는 가장 두드러진 부문입니다.

최종 사용자별로 제약 및 생명 공학 기업이 가장 큰 부문을 차지합니다. 시장은 국가별로도 분할되어 있으며, 2023년 시장 점유율은 중국이 주요하고 있습니다.

아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장의 주요 기업은 Veeva Systems Inc., IQVIA Holdings Inc., AB Cube SAS, ArisGlobal LLC, Oracle Corp, Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health America Holdings, Parexel International Corp, Qinecsa Solutions, Clinevo Technologies 등이 있습니다. 이 회사들은 의약품의 안전성과 약물감시의 실천을 강화하는 혁신적인 솔루션 개발의 최전선에 있습니다.

영문목차

The pharmacovigilance and drug safety software market in the Asia Pacific region was valued at approximately US$ 44.40 million in 2023, with projections indicating it will grow to US$ 68.66 million by 2031. This growth represents a compound annual growth rate (CAGR) of 5.6% from 2023 to 2031.

A significant driver of this market expansion is the integration of advanced technologies such as artificial intelligence (AI), machine learning (ML), and natural language processing (NLP). These technologies are revolutionizing the traditionally resource-intensive processes associated with pharmacovigilance, leading to more informed and efficient operations. Modern pharmacovigilance software platforms are increasingly equipped with sophisticated analytics and AI capabilities that enhance the identification of safety signals. By analyzing large datasets, these tools can uncover correlations and patterns that might be missed by conventional methods. Furthermore, AI-driven predictive analytics can anticipate potential safety issues, enabling companies to implement proactive measures.

Machine learning models are particularly useful in predicting adverse events related to drug use. For example, pharmacovigilance initiatives utilize ML to analyze extensive datasets, identifying patterns that may suggest risks of adverse drug reactions. These algorithms excel at processing unstructured data, such as social media content and patient records, to forecast safety concerns effectively.

Several key players in the market are developing automated AI-based monitoring tools to facilitate drug development for pharmaceutical companies. Notably, in May 2021, Clarivate introduced DialogML, an AI-driven pharmacovigilance literature monitoring software platform. This tool automates the monitoring of pharmacovigilance literature, streamlining processes such as aggregate report generation and safety signal reviews. In January 2024, PubHive Ltd. launched an innovative centralized summary of product characteristics (SmPC) management platform that incorporates AI-powered pharmacovigilance workflows. This platform is designed for life sciences, pharmaceutical companies, and clinical research organizations (CROs), enhancing compliance and operational efficiency for pharmacovigilance teams.

The use of AI systems is increasingly prevalent in real-time drug safety monitoring, which encompasses clinical trial data, medical literature reviews, and patient registries to identify adverse events (AEs). This proactive approach improves the accuracy and speed of adverse drug reaction (ADR) detection. Additionally, NLP technologies enable AI systems to extract pertinent information, such as drug names and symptoms, from extensive textual datasets, facilitating rapid and accurate adverse event reporting. This capability accelerates the identification of new or previously unknown drug safety issues, significantly advancing pharmacovigilance efforts.

The Asia Pacific pharmacovigilance and drug safety software market is segmented into various countries, including India, China, Japan, South Korea, Australia, and the rest of the Asia Pacific region. The region is experiencing a surge in digitization within its healthcare and pharmaceutical sectors. For instance, the Indian government has initiated several programs, such as the Ayushman Bharat Digital Mission and the CoWIN App, aimed at enhancing healthcare accessibility. Similarly, Australia has committed to modernizing its healthcare and pharmaceutical sectors, with a notable investment of US$ 74.91 thousand (AU$ 107.2 thousand) announced in March 2022.

The integration of AI in pharmacovigilance and drug safety software is becoming increasingly common among pharmaceutical companies, which utilize these systems to monitor, collect, analyze, and manage drug safety data. As the demand for pharmacovigilance grows across the region, there is a marked shift towards adopting advanced software solutions. These tools are employed throughout various stages of drug development, including pre-marketing and post-marketing surveillance, as well as during clinical trials. Consequently, the rise in digitalization initiatives within the pharmaceutical sector and the increasing adoption of pharmacovigilance software are expected to drive market growth in the Asia Pacific region.

The market is further categorized based on offerings, deployment methods, enterprise size, software form, functionality, and end users. In terms of offerings, the market is divided into software and services, with the software segment holding a larger share in 2023. Regarding deployment, the cloud segment has also captured a significant market share, reflecting a preference for cloud-based solutions.

When considering enterprise size, large enterprises dominate the market, while the software form is categorized into standard and customized solutions, with standard software leading in market share. Functionality-wise, the market includes segments such as signal and risk management, adverse event tracking, case management, and clinical safety management, with signal and risk management being the most prominent segment.

In terms of end users, pharmaceutical and biotechnology companies represent the largest segment, while the market is also segmented by country, with China leading in market share in 2023.

Key players in the Asia Pacific pharmacovigilance and drug safety software market include Veeva Systems Inc., IQVIA Holdings Inc., AB Cube S.A.S., ArisGlobal LLC, Oracle Corp, Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Inc., Genpact Ltd., Laboratory Corp of America Holdings, Parexel International Corp, Qinecsa Solutions, and Clinevo Technologies. These companies are at the forefront of developing innovative solutions that enhance drug safety and pharmacovigilance practices.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:
3.3 Assumptions and Limitations

4. Asia Pacific Pharmacovigilance and Drug Safety Software Market Landscape

4.1 Overview
4.2 Ecosystem Analysis
4.3 Lit of Vendors in the Value Chain

5. Asia Pacific Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:

6. Asia Pacific Pharmacovigilance and Drug Safety Software Market - Analysis

6.1 Asia Pacific Pharmacovigilance and Drug Safety Software Market Revenue (US$ Thousand), 2021-2031
6.2 Asia Pacific Pharmacovigilance and Drug Safety Software Market Forecast Analysis

7. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis - by Offering

7.1 Software
- 7.1.1 Overview
- 7.1.2 Software: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Services
- 7.2.1 Overview
- 7.2.2 Services: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis - by Deployment

8.1 Cloud
- 8.1.1 Overview
- 8.1.2 Cloud: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 On Premises
- 8.2.1 Overview
- 8.2.2 On Premises: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis - by Enterprise Size

9.1 Large Enterprises
- 9.1.1 Overview
- 9.1.2 Large Enterprises: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.2 SMEs
- 9.2.1 Overview
- 9.2.2 SMEs: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

10. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis - by Form

10.1 Standard
- 10.1.1 Overview
- 10.1.2 Standard: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
10.2 Customized
- 10.2.1 Overview
- 10.2.2 Customized: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

11. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis - by Functionality

11.1 Signal and Risk Management
- 11.1.1 Overview
- 11.1.2 Signal and Risk Management: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11.2 Issue Tracking and Adverse Event Tracking
- 11.2.1 Overview
- 11.2.2 Issue Tracking and Adverse Event Tracking: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11.3 Case Management
- 11.3.1 Overview
- 11.3.2 Case Management: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11.4 Clinical Safety Management and Clinical Trial Safety
- 11.4.1 Overview
- 11.4.2 Clinical Safety Management and Clinical Trial Safety: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11.5 Quality and Compliance
- 11.5.1 Overview
- 11.5.2 Quality and Compliance: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11.6 Medical Writing
- 11.6.1 Overview
- 11.6.2 Medical Writing: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11.7 Audit Support and Training Compliance
- 11.7.1 Overview
- 11.7.2 Audit Support and Training Compliance: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11.8 Healthcare Analytics
- 11.8.1 Overview
- 11.8.2 Healthcare Analytics: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
11.9 Others
- 11.9.1 Overview
- 11.9.2 Others: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

12. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis - by End User

12.1 Pharmaceutical and Biotechnology Companies
- 12.1.1 Overview
- 12.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
12.2 Contract Research Organizations
- 12.2.1 Overview
- 12.2.2 Contract Research Organizations: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
12.3 Business Process Outsourcing (BPO) Firms
- 12.3.1 Overview
- 12.3.2 Business Process Outsourcing (BPO) Firms: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
12.4 Others
- 12.4.1 Overview
- 12.4.2 Others: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

13. Asia Pacific Pharmacovigilance and Drug Safety Software Market - Country Analysis

13.1 Asia Pacific
- 13.1.1 Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
  - 13.1.1.1 Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
  - 13.1.1.2 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 13.1.1.2.1 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Offering
    - 13.1.1.2.2 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Deployment
    - 13.1.1.2.3 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
    - 13.1.1.2.4 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Form
    - 13.1.1.2.5 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Functionality
    - 13.1.1.2.6 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by End User
  - 13.1.1.3 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 13.1.1.3.1 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Offering
    - 13.1.1.3.2 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Deployment
    - 13.1.1.3.3 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
    - 13.1.1.3.4 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Form
    - 13.1.1.3.5 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Functionality
    - 13.1.1.3.6 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by End User
  - 13.1.1.4 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 13.1.1.4.1 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Offering
    - 13.1.1.4.2 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Deployment
    - 13.1.1.4.3 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
    - 13.1.1.4.4 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Form
    - 13.1.1.4.5 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Functionality
    - 13.1.1.4.6 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by End User
  - 13.1.1.5 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 13.1.1.5.1 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Offering
    - 13.1.1.5.2 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Deployment
    - 13.1.1.5.3 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
    - 13.1.1.5.4 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Form
    - 13.1.1.5.5 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Functionality
    - 13.1.1.5.6 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by End User
  - 13.1.1.6 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 13.1.1.6.1 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Offering
    - 13.1.1.6.2 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Deployment
    - 13.1.1.6.3 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
    - 13.1.1.6.4 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Form
    - 13.1.1.6.5 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Functionality
    - 13.1.1.6.6 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by End User
  - 13.1.1.7 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 13.1.1.7.1 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Offering
    - 13.1.1.7.2 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Deployment
    - 13.1.1.7.3 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
    - 13.1.1.7.4 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Form
    - 13.1.1.7.5 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by Functionality
    - 13.1.1.7.6 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share - by End User

14. Competitive Landscape

14.1 Heat Map Analysis by Key Players
14.2 Company Positioning and Concentration

15. Industry Landscape

15.1 Overview
15.2 Market Initiative
15.3 Partnerships and Collaborations

16. Company Profiles

16.1 ArisGlobal LLC
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments
16.2 Max Application
- 16.2.1 Key Facts
- 16.2.2 Business Description
- 16.2.3 Products and Services
- 16.2.4 Financial Overview
- 16.2.5 SWOT Analysis
- 16.2.6 Key Developments
16.3 Oracle Corp
- 16.3.1 Key Facts
- 16.3.2 Business Description
- 16.3.3 Products and Services
- 16.3.4 Financial Overview
- 16.3.5 SWOT Analysis
- 16.3.6 Key Developments
16.4 Veeva Systems Inc
- 16.4.1 Key Facts
- 16.4.2 Business Description
- 16.4.3 Products and Services
- 16.4.4 Financial Overview
- 16.4.5 SWOT Analysis
- 16.4.6 Key Developments
16.5 IQVIA Holdings Inc
- 16.5.1 Key Facts
- 16.5.2 Business Description
- 16.5.3 Products and Services
- 16.5.4 Financial Overview
- 16.5.5 SWOT Analysis
- 16.5.6 Key Developments
16.6 ICON Plc
- 16.6.1 Key Facts
- 16.6.2 Business Description
- 16.6.3 Products and Services
- 16.6.4 Financial Overview
- 16.6.5 SWOT Analysis
- 16.6.6 Key Developments
16.7 Cognizant Technology Solutions Corp
- 16.7.1 Key Facts
- 16.7.2 Business Description
- 16.7.3 Products and Services
- 16.7.4 Financial Overview
- 16.7.5 SWOT Analysis
- 16.7.6 Key Developments
16.8 Accenture Plc
- 16.8.1 Key Facts
- 16.8.2 Business Description
- 16.8.3 Products and Services
- 16.8.4 Financial Overview
- 16.8.5 SWOT Analysis
- 16.8.6 Key Developments
16.9 Syneos Health Inc
- 16.9.1 Key Facts
- 16.9.2 Business Description
- 16.9.3 Products and Services
- 16.9.4 Financial Overview
- 16.9.5 SWOT Analysis
- 16.9.6 Key Developments
16.10 Genpact Ltd.
- 16.10.1 Key Facts
- 16.10.2 Business Description
- 16.10.3 Products and Services
- 16.10.4 Financial Overview
- 16.10.5 SWOT Analysis
- 16.10.6 Key Developments
16.11 AB Cube S.A.S.
- 16.11.1 Key Facts
- 16.11.2 Business Description
- 16.11.3 Products and Services
- 16.11.4 Financial Overview
- 16.11.5 SWOT Analysis
- 16.11.6 Key Developments
16.12 Laboratory Corp of America Holdings
- 16.12.1 Key Facts
- 16.12.2 Business Description
- 16.12.3 Products and Services
- 16.12.4 Financial Overview
- 16.12.5 SWOT Analysis
- 16.12.6 Key Developments
16.13 Parexel International Corp
- 16.13.1 Key Facts
- 16.13.2 Business Description
- 16.13.3 Products and Services
- 16.13.4 Financial Overview
- 16.13.5 SWOT Analysis
- 16.13.6 Key Developments
16.14 Qinecsa Solutions
- 16.14.1 Key Facts
- 16.14.2 Business Description
- 16.14.3 Products and Services
- 16.14.4 Financial Overview
- 16.14.5 SWOT Analysis
- 16.14.6 Key Developments
16.15 Clinevo Technologies
- 16.15.1 Key Facts
- 16.15.2 Business Description
- 16.15.3 Products and Services
- 16.15.4 Financial Overview
- 16.15.5 SWOT Analysis
- 16.15.6 Key Developments

17. Appendix

17.1 About Us
17.2 List of Abbreviations

한글목차

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 상황

제5장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 - 주요 시장 역학

제6장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 분석

제7장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 - 제공 제품별

제8장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 - 전개별

제9장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 - 기업 규모별

제10장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 - 형태별

제11장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 - 기능별

제12장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 분석 - 최종 사용자별

제13장 아시아태평양의 약물감시 및 의약품 안전성 소프트웨어 시장 : 국가별 분석

제14장 경쟁 구도

제15장 업계 정세

제16장 기업 프로파일

제17장 부록